May 28, 2014
11:00 am to 12:00 pm EDT

Sponsored by
Nanostring Technologies

Webinar Description:

~7% of non-small cell lung carcinomas (NSCLC) harbor oncogenic fusions involving ALK, ROS1 and RET. While tumors harboring ALK fusions are highly sensitive to crizotinib, emerging preclinical and clinical data have demonstrated that patients with ROS1 or RET fusions may also benefit from inhibitors targeting these two kinases. Utilizing a transcript-based method, a combination of 3’ over-expression and fusion-specific detection strategies to detect ALK, ROS1 and RET fusion transcripts in NSCLC tumors was designed. Validation of the assay, implemented on the nCounter Analysis System, was performed with 295 NSCLC specimens and shows that the assay is highly sensitive and specific.

During the webinar, a brief introduction tonCounterTechnology will be followed by a detailed description of efforts to develop and validate the multiplexed assay for ALK, ROS1, and RET.

Learning Objectives:

  • Understand the importance of fusions involving ALK, ROS1, and RET genes in lung cancer
  • Case study on the development and validation of a multiplexed assay to detect ALK, ROS1, and RET fusions
  • Comparisons of the multiplexed assay to IHC and FISH
  • Basic introduction to nCounter Technology

Speaker Information

Jay Gerlach
Sr. Marketing Manager, Clinical Markets
Nanostring Technologies

Mao Mao
Senior Vice President of Translational Bioscience and Diagnostics

For Research Use Only. Not for use in Diagnostic Procedures

Cost: No cost